Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Larimar Therapeutics, Inc. Market Cap
The Larimar Therapeutics, Inc. (LRMR) share price is expected to increase by 225.11% over the next year. This is based on calculating the average 12-month share price estimate provided by 0 stock analysts who have covered LRMR. Price targets range from $14 at the low end to $36 at the high end. The current analyst consensus for LRMR is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assigned LRMR 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Larimar Therapeutics, Inc. to perform worse than the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on LRMR. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of LRMR.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Catherine Novack Jones Trading | Buy | $14 | Initiates | Sep 12, 2024 |
| Joel Beatty Baird | Outperform | $16 | Initiates | Sep 4, 2024 |
| Jonathan Wolleben JMP Securities | Market Outperform | $25 | Reiterates | May 31, 2024 |
| Samantha Semenkow Citigroup | Buy | $14 | Maintains | May 22, 2024 |
| Jonathan Wolleben JMP Securities | Market Outperform | $25 | Reiterates | May 21, 2024 |
| Joori Park Leerink Partners | Outperform | $25 | Initiates | Apr 3, 2024 |
| Jonathan Wolleben JMP Securities | Market Outperform | $25 | Reiterates | Mar 15, 2024 |
| Jonathan Wolleben JMP Securities | Market Outperform | $25 | Reiterates | Mar 12, 2024 |
| Samantha Semenkow Citigroup | Buy | $10 | Maintains | Feb 13, 2024 |
| Jonathan Wolleben JMP Securities | Market Outperform | $25 | Maintains | Feb 13, 2024 |
| Samantha Semenkow Citigroup | Buy | $4.5 | Upgrade | Nov 17, 2023 |
| Jonathan Wolleben JMP Securities | Market Outperform | $17 | Reiterates | Aug 15, 2023 |
JMP Securities | Market Outperform | Maintains | Jun 20, 2023 | |
Citigroup | Neutral | Maintains | Jun 8, 2023 | |
| Samantha Semenkow Citigroup | Neutral | $4.5 | Maintains | May 18, 2023 |
| Yatin Suneja Guggenheim | Buy | $14 | Maintains | May 17, 2023 |
| Jonathan Wolleben JMP Securities | Market Outperform | $15 | Reiterates | May 16, 2023 |
Citigroup | Neutral | Maintains | May 15, 2023 | |
| Yatin Suneja Guggenheim | Buy | $12 | Reiterates | Mar 15, 2023 |
JMP Securities | Market Outperform | Maintains | Mar 14, 2023 |
When did it IPO
2014
Staff Count
42
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Carole S. Ben-Maimon M.D.
Market Cap
$459.4M
In 2023, LRMR generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that LRMR's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
No news data available.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
